Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action

Investigational New Drugs

Volumn 15, Issue 1, 1997, Pages 77-86

  Woltering, Eugene A ^a,b   Watson, James C ^a,b   Alperin Lea, R Christian ^a,b   Sharma, Chakravarthi ^a,b   Keenan, Edward ^c   Kurozawa, Daryl ^c   Barrie, Rosemary ^c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Calcium; Proteins; Signal transduction; Somatostatin; Somatostatin receptors; Xanthines

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; BIM 23030; BIM 23034; BIM 23068; CARCINOGEN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; OCTREOTIDE; PENTETREOTIDE; SDZ 204 354; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; VAPREOTIDE; VERAPAMIL;

ACROMEGALY; ANGIOGENESIS; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CORNEA; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM FISTULA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE TUMOR; ENDOTHELIUM CELL; HUMAN; METASTASIS; MONOLAYER CULTURE; NONHUMAN; OVARIECTOMY; POSTGASTRECTOMY SYNDROME; PRIORITY JOURNAL; RABBIT; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR VOLUME; VARICOSIS; VEIN;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CHICK EMBRYO; CHORIONIC VILLI; FEMALE; HORMONE ANTAGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, PROGESTERONE; SOMATOSTATIN;

EID: 0030996856     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005774713202     Document Type: Review

References (30)

1. Krulich L, Dhariwal A, McCann S: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783, 1968
2. Brazeau P, Somatostatin: A peptide with unexpected physiologic activities. Am J Med 71(Suppl. 61B):8-13, 1986
3. Mozell E, Stenzel P, Woltering EA, Rosch J, O'Dorisio TM: Functional Endocrine Tumors of the Pancreas: Clinical Presentation, Diagnosis, and Treatment. St. Louis, MO: Mosby Year Book, 1990
4. Pollak MN, Polychronakos C, Yousefi S, Richard M: Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154(1):326-331, 1988
5. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. JNCI 82(21):1693-1697, 1990
6. Williams ST, Woltering EA, O'Dorisio TM, Fletcher WS: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 157:459-462, 1989
7. Ellison EC, O'Dorisio TM, Woltering EA, Sparks J, Mekhjian HS, Fromkes JJ, Carey LC: Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison Syndrome by long-acting somatostatin (SMS 201-995). Scand J Gastroenterol 21(Suppl. 119):170-176, 1986
8. Richards WO, Geer R, O'Dorisio TM, Robarts T, Parish KL, Rice D, Woltering G, Abumrad NN: Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 49:483-487, 1990
9. O'Dorisio MS, Chen F, O'Dorisio TM, Wray D, Qualman SJ: Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth and Differentiation 5:1-8, 1994
10. Mozell EJ, Woltering EA, O'Dorisio TM: Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy. Disease-a-Month 37(12):751-848, 1991
11. Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau J-P, Yasuda K, Bell GI, Reisine T: Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Molecular Pharmacology 43:838-844, 1993
12. Raynor K, O'Carroll AM, Kong H, Yasuda K, Mahan LC, Bell GI, Reisine T: Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Molecular Pharmacology 44(2):385-392, 1993
13. 3)-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20:716-731, 1993
14. Scheidhauer K, Hildebrand G, Luyken C, Schomacker S, Klug N, Schicha H: Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab res 27(Suppl.):59-62, 1993
15. Hoefnagel CA, Rankin EM, Validesolmos RA, Israelis SP, Pavel S, Janssen AGM: Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamid and indium-111-pentetreotide. Eur J Nucl Med 21:587-588, 1994
16. Woltering EA, O'Dorisio MS, O'Dorisio TM: The role of radiolabeled somatostatin analogs in the management of cancer patients. PPO Updates 9(8):1-16, 1995
17. Sharma C, Alperin-Lea RC, Johnson MA, Burleigh BD, Woltering EA: Inhibition of octreotide acetate (OA) on proliferation of porcine coronary artery smooth muscle, endothelium, and fibroblasts cells. FASEB 9(3):(Abstract), 1995
18. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J: Somatostatin analog Phase I trial in neuroendocrine neoplasms. Acta Oncol 32(2):217-223, 1993
19. Mozell E, Weltering EA, O'Dorisio TM, Fletcher WS, Sinclair AJ, Hill D: Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison Syndrome. SG&O 170(6):476-484, 1990
20. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA: Post-receptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surg 116(6):1148-1152, 1994
21. Barrie R, Woltering EA, Hajarizaheh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55:446-450, 1993
22. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245-251, 1991
23. Bloom SR, Mortimer CM, Thorner MO et al.: Inhibition of gastrin and gastric acid secretion by growth-hormone release-inhibiting hormone. Lancet 2:1106-1109, 1974
24. Heisler S, Reisine TD, Hook VYH, Axelrod J: Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci 79:6502-6506, 1982
25. French MB, Moor BC, Lussier BT, Kraicer J: Protein kinase-C is not essential for growth hormone (GH)-releasing factor-induced GH release from rat somatotrophs. Endocrinology 124:2235-2244, 1989
26. Reisine T: Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary cells. Endocrinology 116:2259-2266, 1985
27. Woltering EA: 1995 (UnPub)
28. Maynes S, Bezos A, Parish C: A novel in vitro assay for human angiogenesis. New Cancer Strategies: Angiogenesis Antagonists (Abstract), 1995
29. Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Forde K, LoGerfo P: Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surg 106:416-422, 1989
30. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C: Somatostatin analog octreotide enhances the antineoplastic effects of tamoxifen and ovarietomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 54(24):6334-6337, 1995